The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around ...

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

“Pfizer beat the numbers and people just yawned. Oh my god the group is so challenged. “But we’re looking for that big win ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

Yahoo Finance Senior Reporter Allie Canal outlines what investors are watching on Tuesday, Nov. 4. Pfizer (PFE), Uber (UBER), ...

Pfizer is in the final stages of a deal to purchase Metsera, offering $47.50 in cash per share and an additional $22.50 if specific performance targets are achieved, as reported by Financial Times.

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

Pfizer has submitted a sweetened bid for obesity drug developer Metsera, as its fight against rival Novo Nordisk escalates, ...